2019
Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis
Gupta A, Hannan A, Maini R, Bitner S, Stone S, Regmi M, Tobian A, Josephson C, Krishnamurti L, Takemoto C, Goel R. Associated Co-Morbidities, Healthcare Utilization, and Mortality in Hospitalized Children and Adults with Hemophilia in the United States: Updated Nationally Representative Estimates and a Comparative Analysis. Blood 2019, 134: 4711. DOI: 10.1182/blood-2019-123161.Peer-Reviewed Original ResearchCongestive heart failureNationwide Inpatient SampleMedian hospital chargesHepatitis CMedian ageHIV/AIDSHospital dischargeInpatient mortalityHeart failureCommon diagnosisHealthcare utilizationHaemophilia patientsHospital chargesMortality rateHemophilia AUtilization Project Nationwide Inpatient SampleYounger ageCommon discharge diagnosesMost hemophilia patientsNon-bleeding complicationsInpatient mortality rateHepatitis C casesCentral line infectionsCoronary artery diseaseInsurance coverage
2017
The portal hypertension syndrome: etiology, classification, relevance, and animal models
Bosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatology International 2017, 12: 1-10. PMID: 29064029, DOI: 10.1007/s12072-017-9827-9.BooksMeSH KeywordsAdrenergic beta-AntagonistsAnimalsAscitesCarcinoma, HepatocellularEarly Detection of CancerEsophageal and Gastric VaricesGastrointestinal HemorrhageHealthy LifestyleHemorrhageHepatic EncephalopathyHepatic VeinsHumansHypertension, PortalHypolipidemic AgentsLigationLiver CirrhosisLiver NeoplasmsModels, AnimalPrognosisSimvastatinConceptsHepatic vein pressure gradientNon-bleeding complicationsPortal hypertensionLiver transplantationDisease stagePortal hypertension syndromeAccurate risk stratificationDevelopment of varicesEndoscopic band ligationAim of treatmentPresent day therapyHealthy life styleBackgroundPortal hypertensionDecompensated patientsHVPG responseRefractory ascitesVariceal bleedingClinical decompensationLarge varicesBand ligationDay therapyHepatic encephalopathyBetter prognosisRisk stratificationEtiologic treatment
2016
Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis
Ripoll C, Augustin S, Reiberger T, Moreau R, Salerno F, Albillos A, Abraldes J, Garcia-Tsao G. Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis. 2016, 333-339. DOI: 10.1007/978-3-319-23018-4_33.Peer-Reviewed Original ResearchComplications of cirrhosisNon-bleeding complicationsNonselective beta blockersBeta blockersLower incidenceSecondary prophylaxisHepatic encephalopathyHepatocellular carcinomaBeneficial effectsLower dysfunction rateNon-hemodynamic effectsDysfunction rateVariceal bleedingCurrent therapiesCovered stentsHemodynamic responseBetter survivalComplicationsCirrhosisBlockersProphylaxisAscitesEarly TIPSIncidencePatientsImpact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding
Augustin S, Albillos A, Ripoll C, Abraldes J, Salerno F, Moreau R, Reiberger T, Garcia-Tsao G. Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding. 2016, 341-353. DOI: 10.1007/978-3-319-23018-4_34.Peer-Reviewed Original ResearchHepatic venous pressure gradientVariceal hemorrhageVariceal bleedingPortal pressureAlpha-1 adrenergic antagonistNon-bleeding complicationsVenous pressure gradientPortal blood flowClinical trial recordsImpact of treatmentDecompensated cirrhosisOral anticoagulantsRefractory ascitesCirrhotic patientsClinical decompensationCohort studyArterial pressureVasoactive drugsRandomized trialsLarge trialsCardiac outputProphylactic useAdrenergic antagonistsClinical dataBlood flow
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply